CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for gynecologic oncologists, gynecologists, medical oncology fellows, nurse practitioners, physician assistants and other healthcare providers involved in the treatment of ovarian cancer.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with ovarian cancer.
  
  LEARNING OBJECTIVES

  • Assess potential biomarkers of response to PARP inhibition, appraise guideline recommendations and consensus statements regarding the indications for and practical implementation of genetic testing in ovarian cancer, and use the results of these assessments in long-term treatment planning.
  • Recognize homologous recombination deficiency as a unique biologic entity, understand how it is measured with commercially available assays, and consider the clinical implications for patients with ovarian cancer.
  • Evaluate available data with olaparib and with niraparib as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced ovarian cancer harboring a deleterious or suspected deleterious BRCA germline or somatic mutation, and provide appropriate counseling on personalized treatment recommendations.
  • Consider the current role of niraparib as maintenance therapy in the first-line setting for patients with advanced ovarian cancer without BRCA mutations, and identify individuals for whom treatment with this strategy may be appropriate.
  • Appreciate available clinical trial data with olaparib/bevacizumab as first-line maintenance therapy for patients with newly diagnosed ovarian cancer responding after first-line platinum/taxane chemotherapy with bevacizumab, in order to determine the role of this novel approach in clinical practice.
  • Compare and contrast the toxicities associated with PARP inhibitors commonly used in therapy for ovarian cancer, and understand the supportive management strategies available to minimize or ameliorate these side effects.

  ACCREDITATION STATEMENTS
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CME CREDIT DESIGNATION STATEMENTS
  CME credit is no longer available for this issue
  
  NCPD CREDIT DESIGNATION STATEMENTS
  NCPD credit is no longer available for this issue
  
  AAPA CREDIT DESIGNATION STATEMENTS
  AAPA credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  ONCC/ILNA CERTIFICATION INFORMATION
  The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/OvarianCancer21/ILNA.
  
  ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  FOR SUCCESSFUL COMPLETION
  Audio Program: This NCPD activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This NCPD activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME and NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Michael J Birrer, MD, PhD
  Director, Winthrop P Rockefeller Cancer Institute
  University of Arkansas for Medical Sciences
  Little Rock, Arkansas
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: OncoQuest Pharmaceuticals Inc (QPT-ORE-005), VBL Therapeutics (VB-111-701/GOG-3018).
  
  Kathleen Moore, MD
  The Virginia Kerley Cade Endowed Chair in Cancer Development
  Associate Director, Clinical Research
  Director, Oklahoma TSET Phase I Program
  Stephenson Cancer Center
  Associate Professor, Section of Gynecologic Oncology
  Director, Gynecologic Oncology Fellowship
  Department of Obstetrics and Gynecology
  University of Oklahoma Health Sciences Center
  Oklahoma City, Oklahoma
  
  Consulting Agreements: Aravive Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Elevar Therapeutics, Genentech, a member of the Roche Group, ImmunoGen Inc, Merck, Mersana Therapeutics, Myriad Genetic Laboratories Inc, Sorrento Therapeutics, Tarveda Therapeutics, Tesaro, A GSK Company, VBL Therapeutics; Contracted Research: PTC Therapeutics, US Department of Defense.
  
  David M O'Malley, MD
  Professor
  Division Director, Gynecologic Oncology
  Co-Director, Gynecologic Oncology Phase I Program
  The Ohio State University and The James Cancer Center
  Columbus, Ohio
  
  Advisory Committee and Consulting Agreements (Personal Fees): AbbVie Inc, Agenus Inc, Ambry Genetics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Elevar Therapeutics, Genentech, a member of the Roche Group, GOG Foundation Inc, ImmunoGen Inc, Iovance Biotherapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Mersana Therapeutics, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, Regeneron Pharmaceuticals Inc, Rubis, Seagen Inc, Tarveda Therapeutics, Tesaro, A GSK Company; Contracted Research (All Funding to Institution): AbbVie Inc, Agenus Inc, Ajinomoto Co Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daré Bioscience, Eisai Inc, EMD Serono Inc, Ergomed Plc, Genentech, a member of the Roche Group, Genmab, GOG Foundation Inc, ImmunoGen Inc, Iovance Biotherapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Ludwig Institute for Cancer Research Ltd, Merck, National Cancer Institute, New Mexico Cancer Care Alliance, Novocure Inc, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Seagen Inc, Stemcentrx, Syneos Health, Tesaro, A GSK Company, TRACON Pharmaceuticals Inc, VentiRx Pharmaceuticals Inc, Yale University; Contracted Research (Personal Fees): Clovis Oncology, Mersana Therapeutics; Data and Safety Monitoring Board/Committee: Watermark Research Partners Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME/NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.
  
  Release date: April 2021
  Expiration date: April 2022
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.